Alpha-GPC pouches are having a moment. Slip one under your lip, wait a few minutes, and — according to the label — you get sharper focus, more drive, and cleaner energy than a cup of coffee. They look like nicotine pouches, they feel like nicotine pouches, and that resemblance is a big part of why people are buying them.
So here’s the honest question, and this article is going to answer it as plainly as possible: do these things actually work? And what does the research really say — not the marketing, the research?
Short version: the ingredient has real science behind it. The pouch does not. And the gap between those two facts is bigger than most brands want you to notice.
What Is Alpha-GPC?
Alpha-GPC (short for L-alpha glycerylphosphorylcholine) is a form of choline — a nutrient your body uses to build brain chemicals. Your brain turns it into acetylcholine, a neurotransmitter, meaning a chemical messenger nerve cells use to talk to each other. Acetylcholine is the one your brain leans on for memory, attention, and learning. So the logic is simple: give the brain more raw material, and it can make more of the messenger it uses to focus.
That logic is why doctors in parts of Europe and in South Korea can actually prescribe Alpha-GPC as a medication for memory problems (National Center for Advancing Translational Sciences, n.d.). In the United States, it is not a drug at all. It’s sold as a dietary supplement, which means no government agency checked it for effectiveness before it hit the shelf.
Do Alpha-GPC Pouches Work?
Nobody has ever studied the pouch. Not once.
This is the part worth sitting with. To check how solid the “pouch” claim is, every registered human trial of Alpha-GPC was reviewed — roughly twenty studies listed on the U.S. government’s clinical trials registry. Every single one used a capsule, a tablet, a softgel, a syrup, or an injection. Not one used a pouch, a lozenge, or anything absorbed through the cheek.
There is also no published research — none, in humans or animals — on whether Alpha-GPC crosses the lining of your mouth at all. That process has a name, buccal absorption, which just means a substance soaking in through the inside of your cheek instead of going down to your stomach. Some drugs do this brilliantly. Nicotine is one of them. But nobody has tested whether Alpha-GPC is one of them.
There’s even a chemistry reason to be skeptical. Alpha-GPC is a large, extremely water-loving molecule, and molecules with that profile usually pass through cheek tissue poorly, not quickly. That’s not proof it fails — it’s just a reason nobody should be promising it succeeds.
Bottom line on the marketing: when a brand tells you their pouch gives you “faster absorption” or “better delivery,” they are not describing a study. They’re describing a hope.
The ingredient, though, has done some real work
Here’s where Alpha-GPC earns some respect. In people with actual memory disease, the evidence is genuinely decent.
In one 180-day trial, 261 people with mild to moderate Alzheimer’s took 1,200 mg per day. Their scores on a standard memory and thinking test improved by 3.2 points, while the placebo group got worse by 2.9 points (De Jesus Moreno Moreno, 2003). A later long-running study called ASCOMALVA added Alpha-GPC on top of donepezil — a standard Alzheimer’s drug — and the combination slowed decline more than the drug alone did over two years (Amenta et al., 2014). The same trial found less depression, anxiety, and apathy in the combination group (Carotenuto et al., 2017), and brain scans after three years showed less shrinkage in memory-related regions (Traini et al., 2020).
Pulling it all together, a 2023 review combined eight studies covering 861 people and found a meaningful average improvement in cognitive scores (Sagaro et al., 2023).
But read the fine print: every one of those participants had a diagnosed brain condition. None of them were healthy people looking for a study boost. And a large share of that research comes from a single lab group in Italy, which is worth knowing whenever one team produces most of the positive findings on one compound.
What about healthy people?
Thinner. Much thinner.
The most-cited study is the motivation one. Thirty-nine healthy adults took 400 mg a day at bedtime for two weeks and reported higher motivation at night, with no change in anxiety (Tamura et al., 2021). That sounds great — but it was single-blind, meaning the researchers knew who got what, which lets expectations leak into the results. The outcome was a self-rating on a phone app. And the effect showed up at one time of day only.
A better-designed 2024 study gave 20 trained men a single dose of either 315 mg or 630 mg. They improved on the Stroop test — a classic task where you name the ink color of a word that spells a different color, which measures mental flexibility. But on the other two thinking tests, working memory and attention, the effect was minimal (Kerksick, 2024). One win out of three.
The Alzheimer’s Drug Discovery Foundation’s independent review puts it bluntly: there is no evidence Alpha-GPC improves thinking in healthy people (Alzheimer’s Drug Discovery Foundation, n.d.).
And the gym claims?
The famous one — that Alpha-GPC causes a 44-fold spike in growth hormone — comes from a study of seven men that was never published as a full peer-reviewed paper. It was a poster at a conference (Ziegenfuss et al., 2008). It is, by a wide margin, the most over-quoted result in this entire category.
The better studies are more mixed. Six days at 600 mg improved lower-body pulling strength in 13 college men but did nothing measurable for upper body (Bellar et al., 2015). A 48-person study found improved jump power — and here’s the odd part, the 250 mg dose beat the 500 mg dose. It also found no effect at all on reaction time or attention (Marcus et al., 2017). More is not automatically better.
Now the Math Problem Nobody Puts on the Can
This is the single most important paragraph in this article.
Commercial Alpha-GPC pouches contain roughly 35 to 85 mg each, with 50–60 mg being typical. The lowest dose that has ever produced a measurable effect in a published study was 250 mg. The clinical trials used 1,200 mg.
| Benefit | Dose Actually Studied | Form Used | Pouches to Match |
|---|---|---|---|
| Memory & thinking (in people with cognitive decline) | 1,200 mg/day | Capsule/tablet | ~20–24 |
| Motivation | 400 mg/day | Capsule | ~7–8 |
| Mental flexibility, single dose | 315–630 mg | Capsule | ~6–12 |
| Jump power | 250 mg/day | Capsule | ~4–5 |
| Growth hormone spike | 600 mg, single dose | Capsule (7-person poster only) | ~10–12 |
| Testosterone support | ❌ No human studies exist | — | — |
So one pouch delivers somewhere between one-fifth and one-twentieth of a dose that has ever done anything in a trial. Online, people report using 4–6 pouches a day and feeling great — which gets closer to a studied dose, but also stacks up caffeine and cost, and still assumes the cheek absorbs it, which nobody has shown.
Honest read: if you feel something from one pouch, a meaningful share of that is likely the caffeine, the flavor, the ritual, and the expectation. Those are real experiences. They’re just not the Alpha-GPC.
Is It Safe? Here’s the Complicated Part
In short-term trials, Alpha-GPC looks mild. A 2024 randomized study gave 100 people 600 mg a day for 12 weeks and found no serious side effects and no more complaints than the placebo group — mostly minor stomach stuff (Jeon et al., 2024). Consumer drug databases also list occasional headache, heartburn, insomnia, dizziness, and skin rash, though without solid numbers behind them (RxList, n.d.).
Then there’s the stroke question, and it deserves a straight answer.
In 2021, researchers tracked 12 million Korean adults over 50 and found that people prescribed Alpha-GPC had about a 43% higher risk of stroke over ten years, with more risk at higher cumulative doses (Lee et al., 2021). That’s an alarming headline. But the authors themselves flagged the catch: Alpha-GPC users were older and sicker to begin with, and were often being treated because they already had early brain changes. Researchers call this confounding by indication — when the reason someone was given a treatment is itself the thing raising their risk.
Then in 2025, a different team using the same national database studied 508,107 people with mild memory problems and found the opposite: Alpha-GPC users had lower stroke risk (Kim et al., 2025).
Two large studies, same country, same data source, opposite conclusions. That is not a settled question, and anyone telling you it is — in either direction — is overselling.
There’s one more mechanism worth knowing. Alpha-GPC carries a chemical group that gut bacteria can convert into TMAO, a compound linked in research to heart and artery disease. In mice, Alpha-GPC raised TMAO and increased artery plaque (Wang et al., 2021). That’s mouse data, not human — but it’s a real reason the safety conversation isn’t finished.
A few practical guardrails:
- The manufacturer’s own filing with the FDA states the ingredient is not intended for anyone under 18 (Chemi Nutra, 2022).
- European food safety regulators concluded Alpha-GPC is safe as a food ingredient up to about 204 mg per day — notably lower than typical U.S. supplement doses (EFSA Panel on Nutrition, Novel Foods and Food Allergens, 2026).
- Total choline from everything you eat and take should stay under 3,500 mg a day for adults; too much causes a fishy body odor, vomiting, sweating, and low blood pressure (National Institutes of Health, Office of Dietary Supplements, 2022).
- Skip it if you’re pregnant or breastfeeding — there simply isn’t enough data (WebMD, n.d.).
- If you’ve had a stroke or heart attack, or you take medications that affect acetylcholine, talk to a doctor first.
And to be completely clear: in 2019 the FDA sent a warning letter to a supplement company partly over its Alpha-GPC marketing, because claiming a supplement treats Alzheimer’s or cognitive decline turns it into an unapproved drug (U.S. Food and Drug Administration, 2019).
Using Alpha-GPC Pouches While Cutting Down on Nicotine
This is the reason a lot of people find this page, so let’s handle it carefully and honestly.
Picture the actual situation. Someone has been on nicotine pouches for a year. Six milligrams, maybe eight or ten a day. They want out. And the thing they dread isn’t only the craving — it’s the emptiness of the gesture. Their hand knows the route to the can. Their lip expects something. Driving, studying, gaming, after eating: the pouch is stitched into the day.
That gesture is the opening, and it’s where a non-nicotine pouch might have something to offer.
First, the part that has to be said plainly
There is no research whatsoever showing Alpha-GPC helps anyone quit nicotine. Not a trial, not a pilot study, not a case report. A thorough search of the medical literature turns up zero human studies of Alpha-GPC for nicotine craving, withdrawal, or quitting. Every claim you’ll see online tracing that connection leads back to a brand’s blog, not a journal.
Alpha-GPC is not an FDA-approved quit aid. The approved list is short and specific: nicotine patch, gum, and lozenge over the counter; nicotine nasal spray and inhaler by prescription; and the prescription pills varenicline and bupropion (U.S. Food and Drug Administration, 2022). That’s it.
So if you use an Alpha-GPC pouch during a taper, be clear about what it is: a placeholder for the habit, not a treatment for the addiction.
Why the theory sounds better than it is
There’s an appealing mechanism here, and it’s worth understanding — along with its limits.
Nicotine works by latching onto nicotinic acetylcholine receptors — docking points on your brain cells that normally receive acetylcholine, that same messenger Alpha-GPC helps build. Nicotine essentially hijacks that system, triggering dopamine release and, over time, causing your brain to build more receptors. When you stop, all those extra receptors sit unfilled. That’s withdrawal (Benowitz, 2010).
So the pitch writes itself: nicotine borrows the acetylcholine system, Alpha-GPC feeds the acetylcholine system, therefore Alpha-GPC should ease withdrawal.
It’s a tidy story. It has not been tested. The closest relatives are a review finding that citicoline — a different choline compound — reduced craving in cocaine use, with nicotine never studied (Wignall & Brown, 2014), and a 2025 experiment in 35 rats where CDP-choline eased nicotine-withdrawal anxiety (Barakat et al., 2025). Rats. Interesting, not actionable.
What the taper evidence actually supports
Now the useful part, because tapering itself has been studied hard.
The biggest surprise in this literature: tapering and quitting cold turkey work about equally well. A Cochrane review — Cochrane being an independent group that pools results across many trials — combined 22 studies covering 9,219 people and found essentially no difference in long-term success between the two approaches (Lindson et al., 2019). One large trial even leaned toward abrupt quitting (Lindson-Hawley et al., 2016).
So the choice between tapering and stopping outright isn’t a scientific question. It’s a personal one: which version will you actually stick with?
What did make a dramatic difference was what you add. In that same review, people who cut down while using a fast-acting nicotine product — gum or lozenge — were more than twice as likely to quit than people who just cut down alone (Lindson et al., 2019). Adding the prescription medication varenicline nearly quadrupled the odds. And across 136 trials with 64,640 participants, nicotine replacement therapy raised quit rates by roughly 55% compared to no treatment (Hartmann-Boyce et al., 2018).
That’s the real headline: the taper isn’t the active ingredient. The support you add to it is.
The four dials you can turn
Rather than handing you a rigid week-by-week calendar — which no study supports and which falls apart the first stressful week anyway — here is the framework people and clinicians actually work with. A taper has four independent dials, and turning one at a time is far more survivable than yanking all four.
- Strength (the milligrams). This is the one people jump to first. Pouches come in real steps: ZYN is sold at 3 mg and 6 mg in the U.S. — the only strengths FDA has authorized for that brand (U.S. Food and Drug Administration, 2025) — while on! runs from 1.5 mg up to 8 mg and Velo offers 2, 4, and 7 mg (Truth Initiative, 2026a). Dropping from 6 mg to 3 mg is roughly a halving. Truth Initiative names this as step one for exactly that reason (Truth Initiative, 2026b).
- Count (how many per day). Often the gentler dial. Track your true daily number for three days first — most people guess low. Then remove the easiest one, not the hardest.
- Timing (when). Push the first pouch of the day later. Cut the last one earlier. Morning and bedtime pouches tend to be the most physically anchored, so shifting them by 30 minutes at a time is a real reduction that doesn’t feel like deprivation.
- Duration (how long it’s in). A pouch reaches peak blood nicotine around 60 minutes in (McEwan et al., 2022). Taking it out at 20 minutes instead of an hour genuinely cuts the dose you absorb, without changing your count at all.
One caution about the milligram dial: the number on the can is not the dose you get. Research measuring actual delivery found labeled strength is a rough guide at best, and that a 4 mg pouch delivers about 92% of a cigarette’s total nicotine over time (Heshmati et al., 2025a). A 4 mg pouch is also nearly identical to a 4 mg nicotine lozenge and delivers roughly twice what 4 mg gum does (Azzopardi et al., 2022). So don’t assume a “small” pouch is a small dose.
Also worth knowing before you plan: nicotine pouches themselves have not been shown to help people quit. A 2025 review of seven randomized trials concluded there’s no significant evidence pouches improve quit rates compared to other products (Heshmati et al., 2025b), and Truth Initiative states outright that using pouches is not a recommended way to quit nicotine in any form (Truth Initiative, 2026c).
Where the Alpha-GPC pouch fits — and where it doesn’t
Habit research explains the appeal. Habits are triggered by context: a place, a time, a feeling reliably pulls the routine out of you before you’ve decided anything (Wood & Rünger, 2016). Get in the car, reach for the can. The cue fires whether or not you’re craving nicotine.
An Alpha-GPC pouch can answer that cue. It occupies the same space, produces a similar tingle and flavor, and satisfies the hand-to-mouth loop — without nicotine. That’s a legitimate use, and it’s the reason people reach for them.
What it can’t do is touch the receptors. When physical withdrawal hits — irritability, anxiety, trouble concentrating, restlessness, appetite changes, trouble sleeping, low mood, symptoms that can begin within 24 hours of cutting back (American Psychiatric Association, 2022) — a non-nicotine pouch is not going to fix that. That’s what nicotine gum and lozenges are for, and they’re cheap, over-the-counter, and backed by 136 trials.
The good news about withdrawal: it’s brutal and it’s brief. Symptoms peak within the first week and mostly clear in two to four (Hughes, 2007). You are not signing up for months of misery. You’re signing up for a bad week.
The setup that makes sense, then, isn’t Alpha-GPC instead of anything. It’s Alpha-GPC handling the ritual while a proven tool handles the chemistry:
- The ritual → a non-nicotine pouch, at the exact moments your hand reaches automatically
- The withdrawal → nicotine gum or lozenge, or a conversation with a doctor or pharmacist about varenicline
- The hard days → a quitline or text program, free, listed at the bottom of this page
And one scheduling detail that trips people up: if your Alpha-GPC pouch contains caffeine, it now has a bedtime. Stop it at least seven hours before you sleep. Quitting nicotine already disrupts sleep on its own; adding late caffeine on top of that is how a taper turns into an exhausted, irritable week that ends in relapse. If you want an evening pouch for the ritual — and evenings are when the ritual bites hardest — use a caffeine-free one.
Two honest guardrails
First, watch for the swap that isn’t a swap. If you were on eight nicotine pouches a day and you’re now on eight Alpha-GPC pouches a day, you’ve kept the compulsion and changed the filling. That may be a real harm reduction — no nicotine is meaningfully better than nicotine — but be clear-eyed that the habit is still driving.
Second, don’t stack them carelessly. Four to six caffeinated pouches a day plus coffee plus an energy drink adds up fast, and jittery and anxious feels almost exactly like nicotine withdrawal. People misread that and relapse thinking the taper failed, when what actually failed was the caffeine math.
What About Sleep?
Many Alpha-GPC pouches include caffeine, which is great at 9 a.m. and a problem at 9 p.m. Caffeine consumed six to seven hours before bed measurably damages sleep quality — including for people who swear it doesn’t affect them, because you can sleep through the night and still lose deep sleep.
If your pouch contains caffeine or any stimulant, stop at least 7 hours before bed. If you want to use pouches in the evening, choose a caffeine-free version.
If You Want to Try Them Anyway
Nothing here says don’t. It says know what you’re buying. If you’re going to try them, the caffeine question is the one that actually changes your day, so pick deliberately:
- Caffeine-free — NZE Caffeine Free Nootropic Pouches (Wintergreen), with Alpha-GPC, L-tyrosine, and L-theanine, no sugar or artificial sweeteners. This is the one for evenings, for anyone tapering nicotine, and for anyone already drinking coffee.
- With caffeine — NZE Energy Nootropic Pouches, for daytime use only. Count this toward your daily caffeine total, and stop seven hours before bed.
Check the label for the actual Alpha-GPC milligrams. Some brands hide it inside a “proprietary blend” and never tell you — which is worth treating as a red flag.
Final Thoughts: Are Alpha-GPC Pouches Worth It?
- The good: Alpha-GPC is a real compound with real evidence — for people with cognitive decline, at 1,200 mg a day, in capsules.
- The gap: A typical pouch holds 50–60 mg. That’s a fraction of any dose that has ever worked in a study.
- The unknown: No study has ever tested a pouch, or whether Alpha-GPC absorbs through your cheek at all.
- The caution: Watch the caffeine, watch your total intake, and know that the stroke question is genuinely unresolved.
- For quitting nicotine: Useful as a ritual replacement. Zero evidence as a treatment. Pair it with something that actually works.
Bottom Line
Alpha-GPC pouches might help — but if they do, it probably isn’t the Alpha-GPC doing it. It’s the caffeine, the ritual, and the moment you take for yourself. Those things have value. Just don’t pay nootropic prices believing you’re getting a clinical dose, and don’t stake a nicotine quit attempt on an ingredient nobody has ever tested for it.
This article is for information only and isn’t medical advice. Talk to a doctor or pharmacist before starting a supplement or planning a nicotine taper, especially if you take medication or have a heart or stroke history.
Free Help for Quitting Nicotine
- 1-800-QUIT-NOW (1-800-784-8669) — free coaching from your state quitline. Spanish: 1-855-DÉJELO-YA (1-855-335-3569).
- SmokefreeTXT — text QUIT to 47848 for 6–8 weeks of daily support from the National Cancer Institute.
- quitSTART app — free craving and trigger tracker from the National Cancer Institute, on iOS and Android.
- EX Program / This is Quitting (Truth Initiative) — free and anonymous text support; text EXPROGRAM to 88709.
- Nicotine gum or lozenge — available over the counter without a prescription, and the most studied taper support there is.
- Your pharmacist — free to talk to, no appointment, and can walk you through NRT dosing in five minutes.
References
Alzheimer’s Drug Discovery Foundation. (n.d.). Alpha-GPC (choline alfoscerate). Cognitive Vitality. https://www.alzdiscovery.org/cognitive-vitality/ratings/alpha-gpc-choline-alfoscerate
Amenta, F., Carotenuto, A., Fasanaro, A. M., Rea, R., & Traini, E. (2014). The ASCOMALVA trial: Interim results after two years of treatment. Journal of Alzheimer’s Disease, 42(s3), S281–S288. https://doi.org/10.3233/JAD-140150
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
Azzopardi, D., Ebajemito, J., McEwan, M., Camacho, O. M., Thissen, J., Hardie, G., Voisine, R., Mullard, G., Cohen, Z., & Murphy, J. (2022). A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. Scientific Reports, 12, 6949. https://doi.org/10.1038/s41598-022-10544-x
Barakat, M., Alzaghari, L. F., Al-Najjar, M. A. A., Al-zuhd, T., Abdaljaleel, M., Abu-Qatouseh, L., Thiab, S., & Alqudah, A. (2025). E-cigarette exposure and CDP choline modulate withdrawal-induced anxiety and hormonal levels in rats. Scientific Reports, 15, 42715. https://doi.org/10.1038/s41598-025-26799-z
Bellar, D., LeBlanc, N. R., & Campbell, B. (2015). The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. Journal of the International Society of Sports Nutrition, 12(1), 42. https://doi.org/10.1186/s12970-015-0103-x
Benowitz, N. L. (2010). Nicotine addiction. New England Journal of Medicine, 362(24), 2295–2303. https://doi.org/10.1056/NEJMra0809890
Carotenuto, A., Rea, R., Traini, E., Fasanaro, A. M., Ricci, G., Manzo, V., & Amenta, F. (2017). The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer’s disease. Journal of Alzheimer’s Disease, 56(2), 805–815. https://doi.org/10.3233/JAD-160675
Chemi Nutra. (2022). New dietary ingredient notification for AlphaSize alpha-glyceryl phosphoryl choline [Submission to U.S. Food and Drug Administration]. Regulations.gov. https://downloads.regulations.gov/FDA-2022-S-0023-0065/attachment_1.pdf
De Jesus Moreno Moreno, M. (2003). Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193. https://doi.org/10.1016/S0149-2918(03)90023-3
EFSA Panel on Nutrition, Novel Foods and Food Allergens. (2026). Safety of L-alpha-glycerylphosphorylcholine from soya phospholipids (lecithin) as a novel food. EFSA Journal, 24(5), Article 10008. https://doi.org/10.2903/j.efsa.2026.10008
Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C., & Lancaster, T. (2018). Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews, 2018(5), CD000146. https://doi.org/10.1002/14651858.CD000146.pub5
Heshmati, J., Bates, E. L., Shahen, S., Visintini, S., Quirouette, E., Mullen, K.-A., & Mir, H. (2025a). Nicotine pouch pharmacokinetics compared to smoked tobacco: A systematic review and meta-analysis. Drug and Alcohol Dependence Reports, 17, 100389. https://doi.org/10.1016/j.dadr.2025.100389
Heshmati, J., Shahen, S., Bates, E. L., Visintini, S., Quirouette, E., Mullen, K.-A., & Mir, H. (2025b). Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials. Addiction. Advance online publication. https://doi.org/10.1111/add.70193
Hughes, J. R. (2007). Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine & Tobacco Research, 9(3), 315–327. https://doi.org/10.1080/14622200701188919
Jeon, J., Lee, S. Y., Lee, S., Han, C., Park, G. D., Kim, S.-J., Chang, J. G., & Kim, W. J. (2024). Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: A randomized double-blind placebo-controlled trial. BMC Geriatrics, 24(1), 774. https://doi.org/10.1186/s12877-024-05366-7
Kerksick, C. M. (2024). Acute alpha-glycerylphosphorylcholine supplementation enhances cognitive performance in healthy men. Nutrients, 16(23), 4240. https://doi.org/10.3390/nu16234240
Kim, H.-K., Park, S., Kim, S.-W., Park, E. S., Hong, J. Y., Hong, I., & Baek, M. S. (2025). Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea. The Journal of Prevention of Alzheimer’s Disease, 12(4), 100059. https://doi.org/10.1016/j.tjpad.2025.100059
Lee, G., Choi, S., Chang, J., Choi, D., Son, J. S., Kim, K., Kim, S. M., Jeong, S., & Park, S. M. (2021). Association of L-α glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Network Open, 4(11), e2136008. https://doi.org/10.1001/jamanetworkopen.2021.36008
Lindson, N., Klemperer, E., Hong, B., Ordóñez-Mena, J. M., & Aveyard, P. (2019). Smoking reduction interventions for smoking cessation. Cochrane Database of Systematic Reviews, 2019(9), CD013183. https://doi.org/10.1002/14651858.CD013183.pub2
Lindson-Hawley, N., Banting, M., West, R., Michie, S., Shinkins, B., & Aveyard, P. (2016). Gradual versus abrupt smoking cessation: A randomized, controlled noninferiority trial. Annals of Internal Medicine, 164(9), 585–592. https://doi.org/10.7326/M14-2805
Marcus, L., Soileau, J., Judge, L. W., & Bellar, D. (2017). Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. Journal of the International Society of Sports Nutrition, 14(1), 39. https://doi.org/10.1186/s12970-017-0196-5
McEwan, M., Azzopardi, D., Gale, N., Camacho, O. M., Hardie, G., Fearon, I. M., & Murphy, J. (2022). A randomised study to investigate the nicotine pharmacokinetics of oral nicotine pouches and a combustible cigarette. European Journal of Drug Metabolism and Pharmacokinetics, 47(2), 211–221. https://doi.org/10.1007/s13318-021-00742-9
National Center for Advancing Translational Sciences. (n.d.). Choline alfoscerate. Inxight Drugs. https://drugs.ncats.io/drug/60M22SGW66
National Institutes of Health, Office of Dietary Supplements. (2022, June 2). Choline: Fact sheet for health professionals. U.S. Department of Health and Human Services. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
RxList. (n.d.). Alpha-GPC. https://www.rxlist.com/supplements/alpha-gpc.htm
Sagaro, G. G., Traini, E., & Amenta, F. (2023). Activity of choline alphoscerate on adult-onset cognitive dysfunctions: A systematic review and meta-analysis. Journal of Alzheimer’s Disease, 92(1), 59–70. https://doi.org/10.3233/JAD-221189
Tamura, Y., Takata, K., Matsubara, K., & Kataoka, Y. (2021). Alpha-glycerylphosphorylcholine increases motivation in healthy volunteers: A single-blind, randomized, placebo-controlled human study. Nutrients, 13(6), 2091. https://doi.org/10.3390/nu13062091
Traini, E., Carotenuto, A., Fasanaro, A. M., & Amenta, F. (2020). Volume analysis of brain cognitive areas in Alzheimer’s disease: Interim 3-year results from the ASCOMALVA trial. Journal of Alzheimer’s Disease, 76(1), 317–329. https://doi.org/10.3233/JAD-190623
Truth Initiative. (2026a, August 12). What is Zyn and what are oral nicotine pouches? https://truthinitiative.org/research-resources/emerging-tobacco-products/what-zyn-and-what-are-oral-nicotine-pouches
Truth Initiative. (2026b, January 12). What to know about quitting Zyn. https://truthinitiative.org/research-resources/emerging-tobacco-products/what-know-about-quitting-zyn
Truth Initiative. (2026c, January 7). Can oral nicotine pouches like Zyn help people quit vaping nicotine? https://truthinitiative.org/research-resources/emerging-tobacco-products/can-oral-nicotine-pouches-zyn-help-people-quit-vaping
U.S. Food and Drug Administration. (2019, February 5). Warning letter: Pure Nootropics, LLC (565425). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-nootropics-llc-565425-02052019
U.S. Food and Drug Administration. (2022, July 21). Want to quit smoking? FDA-approved and FDA-cleared cessation products can help. https://www.fda.gov/consumers/consumer-updates/want-quit-smoking-fda-approved-and-fda-cleared-cessation-products-can-help
U.S. Food and Drug Administration. (2025, January 16). FDA authorizes marketing of 20 ZYN nicotine pouch products after extensive scientific review [Press release]. https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review
Wang, Z., Hazen, J., Jia, X., Org, E., Zhao, Y., Osborn, L. J., Nimer, N., Buffa, J., Culley, M. K., Krajcik, D., van den Born, B. H., Zwinderman, K., Levison, B. S., Nieuwdorp, M., Lusis, A. J., DiDonato, J. A., & Hazen, S. L. (2021). The nutritional supplement L-alpha glycerylphosphorylcholine promotes atherosclerosis. International Journal of Molecular Sciences, 22(24), 13477. https://doi.org/10.3390/ijms222413477
WebMD. (n.d.). Alpha-GPC: Uses, side effects, interactions, dosing. https://www.webmd.com/vitamins/ai/ingredientmono-1087/alpha-gpc
Wignall, N. D., & Brown, E. S. (2014). Citicoline in addictive disorders: A review of the literature. American Journal of Drug and Alcohol Abuse, 40(4), 262–268. https://doi.org/10.3109/00952990.2014.925467
Wood, W., & Rünger, D. (2016). Psychology of habit. Annual Review of Psychology, 67(1), 289–314. https://doi.org/10.1146/annurev-psych-122414-033417
Ziegenfuss, T., Landis, J., & Hofheins, J. (2008). Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. Journal of the International Society of Sports Nutrition, 5(Suppl. 1), P15. https://doi.org/10.1186/1550-2783-5-S1-P15
